Cogent Biosciences, Inc.
Clinical trials sponsored by Cogent Biosciences, Inc., explained in plain language.
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to ease daily misery of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether the experimental drug bezuclastinib can reduce symptoms like itching, flushing, and fatigue in people with nonadvanced systemic mastocytosis, a rare condition where too many mast cells cause chronic discomfort. About 237 adults whose symptoms are …
Phase: PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC